NASDAQ: AZNAstrazeneca PLC Stock
$78.47+0.53 (+0.68%)
Updated Aug 14, 2025
AZN Price
$78.47
Fair Value Price
$86.53
Market Cap
$243.26B
52 Week Low
$61.24
52 Week High
$87.68
P/E
29.33x
P/B
5.44x
P/S
3.83x
PEG
1x
Dividend Yield
1.99%
Revenue
$56.50B
Earnings
$8.30B
Gross Margin
81.4%
Operating Margin
20.68%
Profit Margin
14.7%
Debt to Equity
1.51
Operating Cash Flow
$13B
Beta
0.43
Next Earnings
N/A
Ex-Dividend
Aug 8, 2025
Next Dividend
Sep 8, 2025
AZN Overview
AstraZeneca PLC, is a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of prescription medicines. Its offers products for oncology, cardiovascular, renal, and metabolism diseases, respiratory and immunology, rare diseases, respiratory syncytial virus, Influenza, schizophrenia bipolar disease, gastroenterology, and COVID-19. AstraZeneca was incorporated in 1992 and is headquartered in Cambridge, U.K.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AZN's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: General Drug Manufacturer
Industry Rating
A
AZN
Ranked#6 of 18
Ranked#6 of 18
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.74 | A | |
| $122.09 | A | |
| $134.94 | B |
Be the first to know about important AZN news, forecast changes, insider trades & much more!
AZN News
Overview
Due Diligence Score
–
Industry Average (44)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AZN scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AZN ($78.47) is undervalued by 9.32% relative to our estimate of its Fair Value price of $86.53 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
AZN ($78.47) is not significantly undervalued (9.32%) relative to our estimate of its Fair Value price of $86.53 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AZN ($78.47) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more AZN due diligence checks available for Premium users.
Valuation
AZN fair value
Fair Value of AZN stock based on Discounted Cash Flow (DCF)
Price
$78.47
Fair Value
$86.53
Undervalued by
9.32%
AZN ($78.47) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AZN ($78.47) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AZN ($78.47) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AZN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
29.33x
Industry
34.55x
Market
36.29x
AZN is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
AZN is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
AZN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.44x
Industry
5.87x
AZN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AZN price to earnings growth (PEG)
For valuing profitable companies with growth potential
AZN is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
AZN's financial health
Profit margin
Revenue
$14.5B
Net Income
$2.5B
Profit Margin
16.9%
AZN's Earnings (EBIT) of $11.69B... subscribe to Premium to read more.
Interest Coverage Financials
AZN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$112.4B
Liabilities
$67.6B
Debt to equity
1.51
AZN's short-term liabilities ($33.54B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AZN's long-term liabilities ($34.08B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AZN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AZN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$3.4B
Investing
-$2.1B
Financing
$518.0M
AZN's operating cash flow ($13.39B)... subscribe to Premium to read more.
Debt Coverage Financials
AZN vs General Drug Manufacturer Stocks
Astrazeneca Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.